DSIP FDA Status: Withdrawn Nomination, Rejected Recommendation

DSIP, also called delta sleep-inducing peptide or emideltide, is a synthetic nonapeptide studied since the 1970s mostly in small pharmacology and animal experiments, plus a handful of older clinical studies out of Europe and the former Soviet Union. It is not a prescription drug, not an approved supplement ingredient, and not currently a legal compounded product in the United States. This page covers only its regulatory status. For what the peptide is and how it is theorized to work, see what DSIP is and the mechanism research. For the sleep evidence itself, see the DSIP sleep evidence review.

Is DSIP FDA-approved for anything?

No. There is no FDA-approved drug product containing DSIP or emideltide, for insomnia, stress, pain, or any other indication. Any use of DSIP is off-label in the loosest sense of that phrase, because there is no label to be off of. It has never cleared a New Drug Application review, and nothing in the current record suggests one is pending.

What does "the nomination was withdrawn" actually mean?

DSIP was at one point nominated for FDA's Category 2 list, which flags bulk drug substances that may present significant safety risks for use in compounding. According to the FDA's Category 2 bulk substances page (content current as of 04/22/2026), the DSIP nomination was withdrawn by the nominators themselves, not rejected by FDA on safety grounds and not resolved by any agency determination. See the FDA Category 2 bulk substances list.

This matters because withdrawal closes that particular review without producing a ruling either way. It does not mean FDA looked at DSIP and cleared it. It does not mean the substance is safe for compounding. It just means that specific nomination pathway ended before FDA reached a conclusion.

Is DSIP on the 503A bulks list, and can a compounding pharmacy legally make it?

No. Under Section 503A of the FD&C Act, a bulk drug substance can only be used in compounded preparations if it appears on FDA's 503A bulks list, is the subject of an applicable USP or NF monograph, or is a component of an FDA-approved drug. DSIP meets none of those conditions. It is not on the 503A list, and there is no enforcement discretion policy that covers it. See the FDA 503A bulk substances framework for how that list works and what qualifies a substance for it.

Practically, this means a compounding pharmacy operating within the 503A framework has no current legal basis to compound DSIP as a finished preparation, regardless of what any individual seller markets. Products sold as "DSIP" today are typically research-labeled peptides sold outside the compounding-pharmacy system entirely, which raises separate quality and sourcing questions covered in how to get DSIP and DSIP cost factors.

What happened at the July 2026 advisory committee meeting?

On July 23 to 24, 2026, FDA's Pharmacy Compounding Advisory Committee (PCAC) met and considered emideltide (DSIP) for addition to the 503A bulks list, a separate and later review from the withdrawn Category 2 nomination discussed above. The committee voted against recommending emideltide for that list. See the FDA advisory committee meeting page for July 23-24, 2026 for the official record.

A negative advisory committee vote is not a formal denial by FDA itself, since PCAC recommendations are advisory and FDA makes the final determination. But it is also not a neutral or pending signal. It means the panel reviewing the evidence and safety profile concluded the substance did not meet the bar for legal compounding at this time. Nothing about this vote should be read as momentum toward future approval. If anything, it lengthens the distance between where DSIP is now and any legal compounded pathway.

Reading the two events together, without overstating either one

It is tempting to string "nomination withdrawn" and "committee reviewed it" into a narrative of progress. That is not supported by the record. One event is an incomplete review that never reached a conclusion. The other is a review that reached a conclusion and rejected the substance. Combined, the honest read is: DSIP has been in front of FDA-adjacent bodies twice in different capacities, and neither encounter produced a green light.

DSIP regulatory status decision map, as of September 2026

Use this table as a screening step before evaluating any seller's marketing claims, dosing protocol, or "prescription-grade" language for DSIP.

What should change your read of this status, and what would not

What is established: DSIP has no FDA approval, its 503A path is currently closed, and an advisory committee has formally reviewed and rejected it for that path. These are documented facts from FDA's own pages, not inference.

What is plausible but unproven: that DSIP could someday return through a new nomination with additional safety and manufacturing data. Advisory committee votes are not permanent bans, and substances can be renominated. There is no evidence in the current record that this is happening or scheduled.

What is not established: any timeline for reconsideration, any indication FDA is actively working toward listing DSIP, or any safety conclusion strong enough to call DSIP either cleared or formally banned outright. The honest position sits between those two poles, closer to the rejected side given the committee vote.

For where DSIP sits against a similarly discussed peptide with more clinical history, see the DSIP clinical trials history and the DSIP evidence quality assessment. For a live view of where other peptides in this space stand regulatorily, use the FDA Peptide Status Tracker.

When this matters for a real decision

If someone is considering DSIP for sleep and weighing it against an FDA-approved option, the regulatory picture above should factor into that choice independently of whatever efficacy data exists. An FDA-approved sleep medication carries an approved label, defined dosing, and monitored manufacturing. DSIP currently carries none of those. If sleep problems are significant enough to consider a peptide with this regulatory history, that is also a reasonable point to discuss FDA-approved alternatives with a clinician, including how those are managed if started or stopped; see zolpidem discontinuation and trazodone discontinuation for how tapering is handled with approved agents, and DSIP versus prescription sleep aids for a side-by-side framing.

Persistent, severe insomnia, especially with signs of an underlying medical or psychiatric cause, warrants medical evaluation rather than a peptide sourced outside the regulated supply chain. If sleep loss is accompanied by chest pain, breathing difficulty, suicidal thoughts, or severe confusion, that is an emergency, not a peptide-sourcing question.